Home
Clinical Resources Search
PQI: Neratinib (Nerlynx®) Diarrhea Management

Neratinib (Nerlynx®) Diarrhea Management

Download PQI pdf 0.35MB

Last Updated: October 10, 2023

By: Eric Dallara, RPh

About this PQI

Diarrhea is the main toxicity of neratinib treatment occurring in 95% of patients in the ExteNET trial on the neratinib arm in which antidiarrheal prophylaxis was not protocol specified. 1 Various prevention and treatment strategies for diarrhea have been studied and will be discussed in this document.

More About This PQI

PQI in Action Articles:

neratinib_nerlynx_diarrhea pdf 1MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Breast Cancer Diarrhea TSK Neratinib NERLYNX

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Neratinib (Nerlynx®) Diarrhea Management

About this PQI

More About This PQI

PQI in Action Articles:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Tucatinib (Tukysa®) Management

PQI: The Role of Pharmacy in Equitable Breast Cancer Care

PQI: Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy

PQI: Sacituzumab govitecan (Trodelvy®): Management of Neutropenia and Diarrhea

PQI: Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea

PQI: Oncolytic Induced Diarrhea

PQI in Action: Telotristat Ethyl: Carcinoid Syndrome Diarrhea

PQI: Tivozanib (Fotivda®) for Relapsed or Refractory Advanced Renal Cell Carcinoma

PQI: Temozolomide (Temodar®) for Glioblastoma Multiforme

PQI: Sorafenib (Nexavar®) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)

PQI: Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma

Treatment Support Kit: Neratinib